2004-2008, Quantum Laboratories, Inc.. All rights reserved.

 

 

Schizoaffective Disorders


Protocol AZ 5077IL/0089 (Clears Trial) A Multicenter, open label, flexible dose, parallel group evaluation of the cataractogenic potential of Quetiapine fumarate (SEROQUEL TM ) and Risperidone (RISPERDAL TM ) in the long term treatment of patients with Schizophrenia and Schizoaffective Disorder.

Protocol CN138012-016: A Randomized, Double Blind Comparison of the efficacy and Safety of Aripiprazole Intramuscular Formula, Haloperidol, or Placebo in the treatment of Acutely Agitated Patients with a Diagnosis of Schizophrenia or Schizoaffective Disorder.

Protocol AZ 5077IL/0089 (Clears Trial) A Multicenter, open label, flexible dose, parallel group evaluation of the cataractogenic potential of Quetiapine fumarate (SEROQUEL TM ) and Risperidone (RISPERDAL TM ) in the long term treatment of patients with Schizophrenia and Schizoaffective Disorder.


For more information please call (561) 687-2111

 

 


Our facility identifies and recruits appropriate patients and monitors them during the study. If you qualify and consent to participate, there will be no charge for your study medication and office visits. Additionally, you are responsible for attendence to regular scheduled appointments.


Fact:

During any one-year period, up to 50 million Americans suffer from clearly diagnosable mental disorder involving a degree of incapacity that interferes with employment, attendence at school or daily life.